Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
galmedpharma.investorroom.com
Company Research
Source: Seeking Alpha
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD Company Participants Allen Baharaff - President and Chief Executive Officer Yohai Stenzler - Chief Financial Officer Tali Gorfine - Chief Medical Officer Liat Hayardeny - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Roth Capital Partners Adam Walsh - Stifel Steve Seedhouse - Raymond James Ed Arce - H.C. Wainwright Mayank Mamtani - B. Riley FBR Operator Good day, and welcome to the Galmed Conference Call to discuss Financial Results for Second Quarter of 2019. Today's conference is being recorded. Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements, forecasts regarding anticipated timelines, and expectations with respect to our regulatory and clinical development programs, as well as other statements that relate to
Show less
Read more
Impact Snapshot
Event Time:
GLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLMD alerts
High impacting Galmed Pharmaceuticals Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GLMD
News
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed publishes Results from Aramchol Phase 3 Open Label part in HepatologyPR Newswire
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic DiseasesPR Newswire
GLMD
Sec Filings
- 11/14/24 - Form 6-K
- 11/14/24 - Form F-3
- 11/14/24 - Form 6-K
- GLMD's page on the SEC website